Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
IgA nephropathy (IgAN) represents an important cause of end-stage kidney disease worldwide. Telitacicept has demonstrated potential in attenuating disease progression in IgAN patients. However, whether its efficacy differs between initial and alternative therapy in IgAN patients at high risk of kidney function progress (high-risk IgAN) remains unclear.
We enrolled patients with primary IgAN who exhibited persistent proteinuria (≥ 0.75 g/day) and an estimated glomerular filtration rate (eGFR) ≥ 30ml/min/1.73m2 despite ≥ 3 months of supportive therapy. Participants receiving telitacicept as either initial or alternative treatment were propensity score-matched (1:1) based on baseline proteinuria and eGFR. A control group initiating conventional immunosuppressants (initial IS group) was included for comparison. Efficacy endpoints included renal response rate, changes in proteinuria and eGFR from baseline during follow-up.
Thirty patients were included in each group. At month 3, the initial telitacicept group showed a median proteinuria reduction of 1.47 g/day (79% from baseline), comparable to the initial IS group (1.15 g/day, 48%) but significantly greater than the alternative telitacicept group 0.88 g/d (46%). Concurrently, eGFR remained stable. 25 patients (83.3%) in the initial telitacicept group achieved renal response-a rate significantly higher than in the other two groups. Logistic regression models confirmed independent protective effect of telitacicept on renal response (OR=4.021, p=0.027). No serious adverse events were reported.
Telitacicept appears be a safe and effective treatment for high-risk IgAN patients, significantly reducing proteinuria and preserving renal function. Its therapeutic benefits were more pronounced when used as initial therapy.
